BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Citation
Tu HS, Chen ML, Hong J, He L. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives. World J Gastroenterol 2026; 32(26): 116530 [DOI: 10.3748/wjg.116530]
Full Article (HTML) Full Article (PDF)
(28) (17) (0) (1) (10) (297)
Comments (1)
Andrzej S Tarnawski, MD, PhD, Professor July 13, 2026, 00:25
This timely opinion review provides a concise overview of the emerging role of vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication. It effectively discusses the clinical advantages, current evidence, and challenges to global implementation.
(0) (0) (0)
Please LOGIN to submit a new comment.
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.